The #BIOSECUREAct, now part of the National Defense Authorization Act (#NDAA), will put in motion #US government-wide restrictions on ‘#biotechnology companies of concern’ and eventually bar agencies from procuring their biotech equipment or services.
pharmaphorum.com/news/us-bios...
#BiosecureAct may make its way back into the headlines.
Last year, I wrote for @orf on how the act aims to decouple US supply chains from China, presenting a huge opportunity for India’s pharma industry.
www.orfonline.org/expert-speak...
After a number of key legislative priorities related to cracking down on China failed to make it into the yearly defense bill, Republicans are working...
#NDAA2025 #ChinaCrackdown #BipartisanSecurity #BiosecureAct #USChinaInvestments
From @aayushipratap.bsky.social: the implications of the #BiosecureAct became clearer for the US pharmaceutical and biotechnology industries and the contract firms that supply them. cen.acs.org/business/out...
SugarConeBiotech.com Recent blog post highlighting uncertainties in #biotech planning (pro-tip: share with your Board)
www.sugarconebiotech.com/insights/bio...
#BiosecureAct
#Regulatory
#FDA